Article Sidebar
Published:
Nov 3, 2022Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Effect of butylphthalide in patients with vascular cognitive impairment
Abstract
Purpose: To study the effects of butylphthalide in patients with vascular cognitive impairment.
Method: Sixty patients with vascular cognitive impairment were randomly divided into control group and butylphthalide (NBP) group (n = 30). Control group received blood pressure control, blood sugar control, and lipid-lowering therapies, while NBP group received butylphthalide capsules (200 mg, thrice daily). Treatments in both groups lasted for 14 days. Thereafter, Hasegawa Dementia Scale (HDS), Mini-Mental State Examination (MMSE), Activities of Daily Living Scale (ADL), and event-related potential (P300) were used to evaluate the effects of butylphthalide treatment.
Result: Following 14 days of treatment, HDS, MMSE and ADL scores of NBP group were significantly higher than those of the control group (p < 0.05). The P300 latency of NBP group was shorter than that of control group, while P300 amplitude was higher than that of control group (p < 0.05).
Conclusion: Butylphthalide treatment achieves higher scores of HDS, MMSE and ADL scores, but shorter P300 latency. These results provided good evidence of the effectiveness of butylphthalide therapy in the management of vascular cognitive impairment. However, further clinical trials are recommended prior to application in clinical practice.
